HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

NCTID	NCT04566445 (View at clinicaltrials.gov)
Description	The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD). (Show More)
Development Status	Inactive
Indication	Dry Age-related Macular Degeneration
Disease Ontology Term	DOID:10871; DOID:0110025
Compound Name	GT005
Sponsor	Gyroscope Therapeutics Limited
Funder Type	Industry
Recruitment Status	Terminated
Enrollment Count	255
Results Posted	Not Available

Target Gene/Variant	CFI
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Subretinal
Drug Product Type	Viral vector
Target Tissue/Cell
Delivery System	Viral transduction
Vector Type	AAV2
Editor Type	none
Dose 1	Undisclosed dose 1
Dose 2	Undisclosed dose 2
Dose 3	Undisclosed dose 3
Dose 4
Dose 5

No.of Trial Sites	62
Locations	United States,Poland,United Kingdom,Australia,France,Germany,Spain

Has US IND	True
FDA Designations
Recent Updates	Novartis acquired the company; Study was terminated due to interim analysis demonstrating lack of efficacy